ArticlePloS one2026
Plasma cell-free DNA measured prior to renal replacement therapy initiation is not associated with incident adverse outcomes, hospitalizations or malignancies in chronic kidney disease stage 4-5 patients.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation is an inherent feature of advanced chronic kidney disease (CKD) and associated with adverse outcomes. Several inflammatory biomarkers have been shown to be associated with mortality in CKD. Cell-free DNA (cfDNA) is a novel biomarker for inflammation which has not been previously examined in patients with CKD stage 4-5 not undergoing dialysis. cfDNA was extracted from plasma and quantified with Qubit Flex Fluorometer using dsDNA High Sensitivity kit in 138 patients with CKD stage 4-5 not undergoing dialysis at baseline and at a control time point of median 2.7 years of follow-up. A ratio of control and baseline measurement adjusted for an increment of one year of follow-up was calculated. Associations between cfDNA at baseline and all-cause mortality, major adverse cardiovascular and cerebrovascular events (MACCE, defined as a composite outcome of acute myocardial infarction, coronary revascularization, ischemic or hemorrhagic stroke and cardiovascular death), emergency room (ER) visits, hospitalizations or incident malignancies were assessed. Within a median follow-up of 6.2 years, no associations were observed between cfDNA and mortality, MACCEs, ER visits, hospitalizations or incident malignancies. cfDNA control measurement and cfDNA delta ratio was available in 101 patients. Patients who had received a kidney transplant by the control cfDNA measurement had significantly higher cfDNA delta ratio compared to patients not on renal replacement therapy (RRT) and those undergoing dialysis (p < 0.001 for both comparisons). Patients undergoing dialysis at the time of the control cfDNA measurement had higher cfDNA delta ratio (p = 0.003) compared to patients not on RRT. The present study is the first to show that cfDNA is not associated with adverse outcomes in patients with advanced CKD not undergoing dialysis at baseline. Furthermore, our results provide unique data on the evolution of cfDNA levels in predialysis CKD stage 4-5 patients transitioning to different modalities of RRT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.